Strategic Alliances
Alliance Strategy
DanDrit has built a strong pipeline of dendritic cell based cancer therapies, currently addressing 40% of all cancer-related deaths. DanDrit intends to work with strategic partners to strengthen the in-house pipeline. DanDrit controls key technologies with relevance outside our core business area and these we may out-license or co-develop with suitable partners. Strategic Alliances shall strengthen DanDrit’s pipeline and generate new collaborations and revenues.
DanDrit is seeking partnerships in the following areas:
Licensing-out
Tolerogenic Dendritic Cells
We have developed methods to generate tolerance-promoting dendritic cells for use in the treatment of autoimmune disease (see description in our R & D section). We are looking for an industrial partner or partners to take over the lead in the commercial development of this technology in specific clinical areas, such as type 1 diabetes.
Licensing-in
Technologies relevant to our core dendritic cell cancer therapy business
We would welcome contacts from academic or commercial partners who wish to out-license technologies that may strengthen our core business in cancer therapeutics. These might relate to novel cancer antigens, dendritic cell characterization or related immune technologies.
Joint ventures
Dendritic Cell therapies and relevant technologies
DanDrit may be interested in co-developing aspects of relevant technologies that correspond to in-house needs and partner’s goals. These partnerships might occur on a one to one basis, or a consortium approach might be considered for a relevant knowledge platform.
Current Partnerships:
With Bioneer, Denmark, DanDrit is involved in the development of a Dendritic cell miRNA characterization platform (see Bioneer and miRNA profiling).
For further information on current partnering opportunities please contact:
CEO Mai-Britt Zocca
DanDrit Biotech
Symbion Science Park
Fruebjergvej 3, box 62
DK-2100 Copenhagen, Denmark.
Telephone: +45 2194 7856
E.Mail: mbz@dandrit.com